Promoting research on the therapeutic and other biological properties of minor cannabinoids and terpenes
A group of federal health agencies indicated in a government publication that they wanted to study various " minor cannabinoids of marijuana, as well as cannabis terpenes, to determine how they might best be used to treat a handful of medical conditions.
According to a notice published by the National Institutes of Health, eight of the agency's affiliates hope to fund medical marijuana studies.
Organizations that promote research are the following :
- The National Center for Complementary and Integrative Health, which wants to study “the minor cannabinoids and terpenes of the cannabis plant in relation to pain”.
- The National Cancer Institute, which wants to study "the mechanisms by which minor cannabinoids and terpenes from the cannabis plant may affect cancer interception, cancer treatment and resistance, and the management of cancer symptoms".
- The National Eye Institute, which wants to study “the therapeutic benefits of terpenes and minor cannabinoids in the treatment of glaucoma, retinal degenerations and uveitis”.
- The National Institute on Aging, which wants to study the impact of cannabinoids and terpenes on "age-related cognitive decline/impairment, Alzheimer's disease and Alzheimer's disease-related dementia (AD/ADRD ), weight loss/cachexia, sleep, or conditions in palliative care facilities”.
- The National Institute on Alcohol Abuse and Alcoholism, which wants to study "the role of endocannabinoid systems in alcohol abuse and alcohol-related disorders".
- The National Institute on Drug Abuse, which wants to study "minor cannabinoids in the context of substance use and/or substance use disorder (CDD), and the comorbidity of CCD and HIV infection ".
- The National Institute of Dental and Craniofacial Research, which wants to study "the therapeutic properties of minor cannabinoids and terpenes for dental, oral, or craniofacial diseases or conditions."
- The National Institute of Neurological Disorders and Stroke, which wants to study the effects of minor cannabinoids and terpenes on "pain, migraine, headaches, epilepsy, movement disorders, neurodegenerative disorders and strokes ".
Studies will focus on cannabinoids such as CBD, CBN, CBG, and delta-8 THC, rather than delta-9 THC which is the most well-known cannabinoid that gets users "high".